Recurrent focal amplifications of BRD9 have been associated with tumorigenicity in several cancers and inhibition of BRD9 was found to suppress breast, ovarian, gastrointestinal stromal cancer, and prostate tumor growth [38,173,174] as well as proliferation of acute myeloid leukemia cells [37]. Here, BRD9 is linked to cancer.